What are the clinical features of Langerhans cell histiocytosis?

Clinical Features of Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare hematopoietic neoplasm with highly variable clinical presentations ranging from isolated bone or skin lesions to life-threatening multisystem disease, most commonly affecting bone (62-77%), followed by central nervous system (34%), lung (28%), skin, and lymph nodes. 1

Key Epidemiologic Features

• Incidence: 1-1.5 cases per million population per year in adults 1
• Age distribution: Can occur at any age; median age at diagnosis is 42-46.5 years in adults 2, 3
• Sex: Slight male predominance (60.8%) in adults 2
• Time to diagnosis: Often delayed (median 8 months from symptom onset) 3

Organ-Specific Clinical Manifestations

Skeletal System (Most Common: 62-77%)

• Punched-out lytic bone lesions with beveled edges, predominantly affecting flat bones 1
• Distribution: Skull (39.9% of bone lesions), followed by ribs, sternum, pelvis, and long bones 4
• Presents with localized pain, swelling, or pathologic fractures
• Vertebral involvement can cause vertebra plana (complete vertebral collapse)

Central Nervous System (34%)

• Diabetes insipidus is the hallmark endocrine manifestation 1
• Hypothalamic-pituitary axis involvement with characteristic MRI findings (increased FLAIR signal in hypothalamus) 1
• Neurodegenerative disease pattern: cerebellar involvement with ataxia, dysarthria, cognitive impairment 1
• Mass lesions in posterior midbrain/pons 1

Pulmonary System (28%)

• Upper lobe-predominant nodular and cystic lesions in smokers 1
• Three radiographic patterns: nodulocystic (most common), cystic-predominant, or confluent with fibrosis 1
• Presents with dyspnea, cough, chest pain, or spontaneous pneumothorax
• Important: Single-system pulmonary LCH has unique smoking-related etiopathogenesis 1

Skin (3.8-14%)

• Erythematous, reddish-brown, or skin-colored crusted/scaly papules or maculopapular lesions 5
• Can present as plaques, patches, vesicles, or urticarial lesions
• Often mimics common dermatoses (seborrheic dermatitis, eczema), leading to delayed diagnosis
• Frequently involves scalp, trunk, and intertriginous areas

Hepatic System

• Infiltrative pattern on imaging with bile duct involvement 1
• Can present as sclerosing cholangitis pattern 6
• Portal area involvement with bile duct epithelial injury and eosinophil infiltration 6
• May cause cholestasis, hepatomegaly, or liver dysfunction

Lymph Nodes (6.9%)

• Cervical, axillary, or generalized lymphadenopathy
• FDG-avid on PET/CT imaging 1

Disease Classification Patterns

Unifocal Disease (Most Common in Adults: ~40-48%)

• Solitary lesion in any organ
• Best prognosis with local treatment options
• Most commonly bone lesions

Single-System Multifocal Disease

• Multiple lesions within one organ system
• Requires systemic evaluation to exclude multisystem involvement

Multisystem Disease (53-60%)

• Involvement of ≥2 organ systems
• Higher risk of complications and mortality
• Requires comprehensive staging and systemic therapy

Single-System Pulmonary LCH

• Distinct category due to smoking-related etiology
• 85% harbor MAPK pathway mutations despite smoking association 1
• May spontaneously resolve with smoking cessation

Critical Diagnostic Clues

Histopathologic Features

• Mononuclear cells with characteristic grooved/coffee bean-shaped nuclei and abundant eosinophilic cytoplasm 1
• Mixed inflammatory infiltrate with prominent eosinophils (eosinophilic abscesses in 21.5%) 4
• Multinucleated giant cells present in 62.6% of cases 4

Immunophenotype (Essential Triple Panel)

• CD1a positive (100% sensitivity) 4
• Langerin/CD207 positive (98.5% sensitivity) 4
• S-100 positive (99.1% sensitivity) 4
• CD68 shows cytoplasmic Golgi dot-like pattern 1
• CD163 negative (distinguishes from other histiocytic disorders) 1

Molecular Features

• BRAF V600E mutation in 36-50% of cases (detectable by VE1 immunohistochemistry) 1
• Other MAPK pathway mutations (MAP2K1, ARAF, NRAS, KRAS) in BRAF-wild-type cases 1
• Kinase fusions (BRAF, ALK, NTRK1) in rare cases 1
• BRAF V600E in plasma cell-free DNA associated with worse prognosis and CNS/pituitary involvement 2

Associated Conditions and Pitfalls

High Incidence of Concomitant Malignancies (22.1%)

• Myeloid neoplasms (AML, MPN, CMML) 1
• Lymphomas (may show LCH-like lesions as bystander phenomenon) 1
• Solid tumors: lung cancer (especially in pulmonary LCH due to smoking), thyroid cancer, renal cell carcinoma 1
• Critical: Screen for second malignancies before, during, and after LCH diagnosis

Mixed Histiocytosis

• Can coexist with Erdheim-Chester disease (ECD) or Rosai-Dorfman disease (RDD) 1
• LCH/ECD overlap shows high BRAF V600E frequency (69-82%) 1
• May occur sequentially or concomitantly

Prognostic Features

Favorable Factors

• Unifocal or single-system disease
• Age <60 years at diagnosis 2
• Response to initial chemotherapy
• Overall 5-year survival: 90.6% in adults 2

Poor Prognostic Indicators

• Age ≥60 years at diagnosis 2
• Multisystem disease with organ dysfunction
• Non-response to initial chemotherapy (LCH-related deaths occur in poor responders) 2
• BRAF V600E positivity in plasma cell-free DNA 2
• 5-year event-free survival only 52.1% due to high relapse rates 2

Common Clinical Pitfalls

1. Delayed diagnosis due to non-specific symptoms and mimicry of common conditions
2. Failure to obtain tissue biopsy for definitive diagnosis and molecular testing
3. Incomplete staging missing multisystem involvement
4. Not screening for concomitant malignancies (present in >20% of cases)
5. Misdiagnosing pulmonary LCH as other cystic lung diseases without considering smoking history
6. Missing diabetes insipidus as presenting feature of CNS involvement
7. Inadequate follow-up given high relapse rates (event-free survival only 52% at 5 years)